ArticleFrontiers in molecular biosciences2026
Discovery of metabolite biomarkers for cerebral ischemia-reperfusion injury based on metabolomics: neurotoxic mechanism and functional validation of a flavopiridol -related metabolite.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the role and potential mechanism of metabolite alterations during cerebral ischemia-reperfusion injury (CIRI) and to explore novel candidate molecular markers for the diagnosis of this disease. Methods: A rat model of middle cerebral artery occlusion was established using the modified Longa EZ intraluminal suture method. The infarct status was comprehensively evaluated by neurological deficit score (mNSS), TTC staining, HE staining, and Nissl staining. Serum metabolite changes after CIRI were detected using non-targeted metabolomics, and the potential toxic effects of significantly altered metabolites were predicted using the ProTox tool. Subsequently, bioinformatics analysis was employed to identify core targets and key pathways associated with the metabolite of interest, followed by molecular docking and molecular dynamics simulations to predict their interactions. Results: Metabolomic analysis identified 41 significantly upregulated and 232 downregulated metabolites. Among the significantly altered metabolites, a flavopiridol-related metabolite (FRM) exhibited potential neurotoxic characteristics. A total of 193 CIRI-related core targets were associated with this metabolite, from which 10 core targets and 15 key pathways were further screened. ROC analysis suggested that this metabolite possessed good discriminatory ability (AUC = 0.94). Molecular docking results showed binding energies of less than -7 kcal/mol for all core targets. A 100 ns molecular dynamics simulation indicated that the complex formed by the FRM and SRC remained structurally stable, as evidenced by balanced RMSD, Rg, SASA, and P-L-RMSD values. The calculated binding free energy was -32.48 kcal/mol, with key residues LEU-393, MET-341, and GLU-339 contributing significantly to the interaction, suggesting potential biological activity. Conclusion: This study reveals a complex metabolic reprogramming phenomenon during CIRI and preliminarily identifies a FRM as a potential candidate molecular marker and possible interventional target, providing a new theoretical basis and directions for future research on the diagnosis and treatment of CIRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.